Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GSK Researchers Suppressed Data from China Tests of MS Drug

publication date: Jul 23, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Two years ago, an internal audit of practices at GlaxoSmithKline’s Shanghai R&D facility showed serious problems. Researchers did not report a total of six test results of a multiple sclerosis drug. By the time the tests were discovered, the drug, ozanezumab, was already being tested in humans. When GSK officials looked at the data, they stopped testing the drug in patients with MS, though trials for Lou Gherig’s disease were allowed to continue. The New York Times obtained a copy of the audit and broke the story, which was not previously known. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...